Almost 1.3 million Peruvians suffer from type 2 diabetes, but only 30% control their evil, said Jaime Villena, head of the Peruvian Society of Endocrinology.
In that sense, Jansee laboratories presented the Canagiglozine medicine, which allows better glucose control, overweight and blood pressure, reducing sugar through the kidneys.
Similarly, it delays the disease process, said the expert.
Canagliflozine is an inhibitor of the transport protein of the Glucose Subtype 2 (SGLT2) responsible in 90% of the reabsorption of glucose by the kidneys.The collide of glucose reabsorption causes it to be eliminated through urine.Canagliflozine is used in type 2 diabetes in monotherapy or associated with other hypoglycemianes.